Because angiogenic endothelial cells of the
tumor vasculature represent an interesting target to potentiate the antivascular effect of
photodynamic therapy, we recently described the conjugation of a
photosensitizer [5-(4-carboxyphenyl)-10,15,20-triphenylchlorin (TPC)], via a spacer [
6-aminohexanoic acid (Ahx)], to a
vascular endothelial growth factor receptor-specific heptapeptide [H-
Ala-Thr-Trp-Leu-Pro-Pro-Arg-
OH (ATWLPPR)] and showed that
TPC-Ahx-ATWLPPR binds to
neuropilin-1. Because
peptides often display low stability in
biological fluids, we examined the in vivo and in vitro stability of this conjugate by high-performance liquid chromatography and matrix-assisted
laser desorption ionization/time of flight mass spectrometry.
TPC-Ahx-ATWLPPR was stable in vitro in human and mouse plasma for at least 24 h at 37 degrees C but, following i.v. injection in
glioma-bearing nude mice, was degraded in vivo to various rates, depending on the organ considered. TPC-Ahx-A was identified as the main metabolic product, and biodistribution studies suggested that its appearance in plasma mainly resulted from the degradation of the peptidic moiety into organs of the reticuloendothelial system. According to in vitro cell culture experiments,
TPC-Ahx-ATWLPPR was also significantly degraded after incorporation in human umbilical vein endothelial cells (HUVEC), mainly into TPC-Ahx-A and to a lesser extent into TPC-Ahx-AT and TPC-Ahx-ATWLPP.
TPC-Ahx-ATWLPPR mostly localized into lysosomes, and when HUVEC were treated with the lysosomal
enzymes' inhibitor
ammonium chloride, this resulted in a significant decrease of the
peptide degradation. This study provides essential information for the choice of the time of activation of the
photosensitizer (
drug-light interval) not to be exceeded and for the future design of more stable molecules.